Erasca (ERAS) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
ERAS rises 1.2% to $14.87 on 1.9x normal volume. Closed at $14.87, +1.16% vs the prior close of $14.70. Day range $14.36–$15.26, opened at $14.71.
ERAS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ERAS rises 1.2% to $14.87 on 1.9x normal volume
- Closed at $14.87, +1.16% vs the prior close of $14.70. Day range $14.36–$15.26, opened at $14.71.
- Volume was 8.48M shares, 1.9x its 50-day average of 4.37M — unusually heavy trading.
- Price is -8.7% vs its 50-day average ($16.29) and +2.6% vs its 200-day average ($14.49).
- 52-week range $2.11–$24.28; today's close sits at 58% of that range, 38.8% below the 52-week high.
Oct 14, 2026 — ERAS dips 0.5% to $14.70, 3 down days in a row
- Closed at $14.70, -0.54% vs the prior close of $14.78. Day range $14.29–$15.08, opened at $14.41.
- Volume was 4.75M shares, 1.1x its 50-day average of 4.37M.
- Price is -10.2% vs its 50-day average ($16.36) and +1.8% vs its 200-day average ($14.44).
- 52-week range $2.11–$24.28; today's close sits at 57% of that range, 39.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ERAS slides 4.4% to $14.78
- Closed at $14.78, -4.40% vs the prior close of $15.46. Day range $14.50–$15.58, opened at $15.25.
- Volume was 5.31M shares, 1.2x its 50-day average of 4.32M.
- Price is -10.1% vs its 50-day average ($16.44) and +2.8% vs its 200-day average ($14.38).
- 52-week range $2.11–$24.28; today's close sits at 57% of that range, 39.1% below the 52-week high.
Oct 12, 2026 — ERAS slides 3.6% to $15.46
- Closed at $15.46, -3.56% vs the prior close of $16.03. Day range $15.32–$16.01, opened at $15.89.
- Volume was 4.28M shares, 1.0x its 50-day average of 4.29M.
- Price is -6.3% vs its 50-day average ($16.50) and +7.9% vs its 200-day average ($14.33).
- 52-week range $2.11–$24.28; today's close sits at 60% of that range, 36.3% below the 52-week high.
Oct 9, 2026 — ERAS jumps 3.7% to $16.03 on 1.8x normal volume
- Closed at $16.03, +3.69% vs the prior close of $15.46. Day range $15.22–$16.20, opened at $15.42.
- Volume was 7.77M shares, 1.8x its 50-day average of 4.21M — unusually heavy trading.
- Price is -3.2% vs its 50-day average ($16.55) and +12.4% vs its 200-day average ($14.26).
- 52-week range $2.11–$24.28; today's close sits at 63% of that range, 34.0% below the 52-week high.
Oct 8, 2026 — ERAS jumps 9.5% to $15.46 on 2.3x normal volume
- Closed at $15.46, +9.49% vs the prior close of $14.12. Day range $13.78–$15.62, opened at $13.96.
- Volume was 9.61M shares, 2.3x its 50-day average of 4.10M — unusually heavy trading.
- Price is -6.9% vs its 50-day average ($16.60) and +8.9% vs its 200-day average ($14.20).
- 52-week range $2.11–$24.28; today's close sits at 60% of that range, 36.3% below the 52-week high.
Oct 7, 2026 — ERAS dips 1.3% to $14.12, 3 down days in a row
- Closed at $14.12, -1.26% vs the prior close of $14.30. Day range $13.93–$14.57, opened at $14.09.
- Volume was 3.85M shares, 0.9x its 50-day average of 4.10M.
- Price is -15.2% vs its 50-day average ($16.65) and -0.2% vs its 200-day average ($14.14).
- 52-week range $2.11–$24.28; today's close sits at 54% of that range, 41.8% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — ERAS dips 2.9% to $14.30 on 2.0x normal volume
- Closed at $14.30, -2.85% vs the prior close of $14.72. Day range $14.02–$14.93, opened at $14.74.
- Volume was 8.04M shares, 2.0x its 50-day average of 4.01M — unusually heavy trading.
- Price is -14.5% vs its 50-day average ($16.73) and +1.5% vs its 200-day average ($14.09).
- 52-week range $2.11–$24.28; today's close sits at 55% of that range, 41.1% below the 52-week high.
Oct 5, 2026 — ERAS ends flat (-0.1%) to $14.72
- Closed at $14.72, -0.14% vs the prior close of $14.74. Day range $13.80–$15.03, opened at $14.74.
- Volume was 5.49M shares, 1.4x its 50-day average of 3.96M.
- Price is -12.5% vs its 50-day average ($16.82) and +4.9% vs its 200-day average ($14.04).
- 52-week range $2.11–$24.28; today's close sits at 57% of that range, 39.4% below the 52-week high.
Oct 2, 2026 — ERAS rises 1.1% to $14.74
- Closed at $14.74, +1.10% vs the prior close of $14.58. Day range $14.57–$15.27, opened at $14.81.
- Volume was 3.84M shares, 1.0x its 50-day average of 3.96M.
- Price is -12.8% vs its 50-day average ($16.91) and +5.4% vs its 200-day average ($13.98).
- 52-week range $2.11–$24.28; today's close sits at 57% of that range, 39.3% below the 52-week high.
ERAS latest news & SEC filings
Every SEC filing by or about ERAS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 24, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 17, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 12, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 11, 2026 · S-8 — Registration of shares for employee stock plans (S-8)
Registration of shares for employee stock plans (S-8)
Aug 11, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$44.08M (prior year -$33.88M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.12) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 10, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 21, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 14, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 14, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade ERAS
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 12, 2026, Jan 20, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.93% (largest 10.3%).
- Liquidity: about 5.44M shares (≈$80.83M) trade per day on average.
- 52-week position: $14.87 vs a range of $2.11–$24.28 (58% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 3 sales; latest: Ebun Garner sold 80,000 shares on Apr 1, 2026.
- Latest filings: 8-K Oct 16, 2026; 8-K Aug 24, 2026; 10-Q Aug 11, 2026.
- Share count: 349.76M shares outstanding (Aug 4, 2026), +23.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ERAS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 14.71 | 15.26 | 14.36 | 14.87 | 8.48M |
| Oct 14, 2026 | 14.41 | 15.08 | 14.29 | 14.70 | 4.75M |
| Oct 13, 2026 | 15.25 | 15.58 | 14.50 | 14.78 | 5.31M |
| Oct 12, 2026 | 15.89 | 16.01 | 15.32 | 15.46 | 4.28M |
| Oct 9, 2026 | 15.42 | 16.20 | 15.22 | 16.03 | 7.77M |
| Oct 8, 2026 | 13.96 | 15.62 | 13.78 | 15.46 | 9.61M |
| Oct 7, 2026 | 14.09 | 14.57 | 13.93 | 14.12 | 3.85M |
| Oct 6, 2026 | 14.74 | 14.93 | 14.02 | 14.30 | 8.04M |
| Oct 5, 2026 | 14.74 | 15.03 | 13.80 | 14.72 | 5.49M |
| Oct 2, 2026 | 14.81 | 15.27 | 14.57 | 14.74 | 3.84M |
| Oct 1, 2026 | 14.66 | 15.01 | 14.33 | 14.58 | 3.69M |
| Sep 30, 2026 | 14.37 | 15.12 | 14.11 | 14.66 | 5.29M |
| Sep 29, 2026 | 14.10 | 14.43 | 13.82 | 14.21 | 3.20M |
| Sep 28, 2026 | 14.52 | 14.61 | 13.86 | 14.13 | 3.60M |
| Sep 25, 2026 | 14.62 | 14.89 | 14.23 | 14.25 | 3.22M |
| Sep 24, 2026 | 13.82 | 15.07 | 13.53 | 14.52 | 6.27M |
| Sep 23, 2026 | 15.55 | 15.55 | 13.94 | 13.94 | 4.42M |
| Sep 22, 2026 | 15.17 | 15.77 | 15.09 | 15.55 | 4.77M |
| Sep 21, 2026 | 14.96 | 15.29 | 14.60 | 15.04 | 4.15M |
| Sep 18, 2026 | 15.41 | 15.47 | 14.51 | 14.77 | 8.69M |
About Erasca
Erasca (ERAS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1761918.
ERAS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James Arthur Bristol | Director | Jun 29, 2026 |
| Alexander W. Casdin | Director | Jun 29, 2026 |
| Julie Hambleton | Director | Jun 29, 2026 |
| Jean I Liu | Director | Jun 29, 2026 |
| Jonathan E Lim | Chairman & CEO | Jan 30, 2026 |
| Pratik S Multani | Director | Jun 29, 2026 |
| Valerie Denise Harding Start | Director | Jun 29, 2026 |
| Michael David Varney | Director | Jan 30, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David M. Chacko | CFO and CBO | Jan 30, 2026 |
| Charles S. Fuchs | President, R&D | Aug 12, 2026 |
| Ebun Garner | Chief Legal Officer | Apr 3, 2026 |
| Jonathan E Lim | Chairman & CEO | Jan 30, 2026 |
| Shannon Morris | Chief Medical Officer | Mar 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 1, 2026 | Ebun Garner | Sale | 80,000 | $16.40 |
| Mar 4, 2026 | Shannon Morris | Sale | 20,000 | $15.04 |
| Jan 7, 2026 | Ebun Garner | Sale | 120,000 | $5.59 |
ERAS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-124.55M | -0.44 | $-95.45M |
| Dec 31, 2024 | — | $-161.65M | -0.69 | $-109.42M |
| Dec 31, 2023 | — | $-125.04M | -0.83 | $-101.22M |
| Dec 31, 2022 | — | $-242.81M | -1.99 | $-103.26M |
| Dec 31, 2021 | — | $-122.76M | -1.85 | $-79.60M |
Latest balance sheet: total assets $435.05M, total liabilities $73.19M, cash $42.54M (as of Jun 30, 2026).
ERAS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $18.31 |
| May 11, 2026 | 8-K Item 2.02 (results) | $10.44 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $14.65 |
| Jan 20, 2026 | 8-K Item 2.02 (results) | $9.81 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $2.65 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.56 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.33 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $1.48 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $2.99 |
| Aug 12, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ERAS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.